Bicara chases Merus
But ficerafusp is limited to HPV-negative disease, and petosemtamab’s safety looks better.
ASCO 2024 preview – with more patients Merus claims better efficacy
Early release of petosemtamab’s ASCO data suggest that analysts’ bull case has been met.
ASCO 2024 abstract movers – Merus convinces, at first
Thursday's unveiling of regular ASCO abstract yielded a few initial winners and losers.
ASCO 2024 preview – Merus’s home run remains unconfirmed
Petosemtamab meets sellside forecasts, but for the bull case you need to include an unconfirmed response.
Merus’s big bispecific test approaches
Hopes are high for petosemtamab head and neck data at ASCO, but what does a win look like?
ASCO 2024 preview – Astra’s plenary double
Abstract titles reveal some of ASCO’s key datasets.
ESMO Asia 2023 – deaths raise doubts about Merus’s Rybrevant challenger
Merus still hopes for a future for MCLA-129, but the doors are closing.
